Disease · MONDO_0019783
Trials13
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
1 to 13 of 13
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02396316 | Japanese Phase 3 Study of Aflibercept in Neovascular Glaucoma Patients | Phase 3 | 54 | 2017-07-21 | Glaucoma, Neovascular | AFLIBERCEPT | Its record names the disease | ClinicalTrials.gov |
| NCT03639675 | Study to Learn How the Drug Aflibercept Works in in Japanese Patients With Increased Eye Pressure That is Caused by New Blood Vessels Growing in the Eye (Neovascular Glaucoma or NVG). Safety of the Drug and Patients' Tolerability of the Drug Injection is Also Studied | Phase 3 | 16 | 2020-02-18 | Glaucoma, Neovascular | AFLIBERCEPT | Its record names the disease | ClinicalTrials.gov |
| NCT01225146 | Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2) | Phase 1 | 8 | 2017-08-14 | Ischemia, Retinal Vein Occlusion, Pathologic Processes, Retinal Diseases, Eye Diseases | RANIBIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01711879 | Use of Intravitreal Aflibercept Injection for Neovascular Glaucoma | Not applicable | 7 | 2021-01-05 | Neovascular Glaucoma | AFLIBERCEPT | Its record names the disease | ClinicalTrials.gov |
| NCT04519619 | Study to Learn More About Safety of Aflibercept Injection in Japanese Patients With Neovascular Glaucoma (NVG) | 480 | Neovascular Glaucoma | AFLIBERCEPT | Its record names the disease | ClinicalTrials.gov | ||
| NCT02067013 | Analysis of Aqueous and Vitreous Humor | Phase 2 | 45 | Proliferative Diabetic Retinopathy, Macular Degeneration, Macular Hole, Neovascular Glaucoma | RANIBIZUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT00441181 | Effects of Travoprost on Neovascular Glaucoma | Not applicable | 40 | Neovascular Glaucoma | TRAVOPROST | Its record names the disease | ClinicalTrials.gov | |
| NCT02914626 | Intravitreal Ranibizumab (Lucentis®) for Neovascular Glaucoma- a Randomized Controlled Study | Phase 3 | 28 | Glaucoma, Neovascular, Ranibizumab | RANIBIZUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT00384631 | Intravitreal Bevacizumab for Neovascular Glaucoma | Not applicable | 26 | Neovascular, Glaucoma | BEVACIZUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT01370135 | Study to Evaluate the Effects of Ranibizumab (Lucentis) for Patients With Rubeosis and Neovascular Glaucoma | Not applicable | 20 | Neovascular Glaucoma, Rubeosis | RANIBIZUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT04970251 | Aflibercept as Adjunctive Treatment for Filtration Surgery in Neovascular Glaucoma | Not applicable | 5 | Intraocular Pressure, Neovascular Glaucoma, Vascular Endothelial Growth Factor Overexpression, Glaucoma Secondary to Eye Inflammation | AFLIBERCEPT | Its record names the disease | ClinicalTrials.gov | |
| NCT02641457 | Intravitreal Aflibercept or Ranibizumab for Rubeosis Iridis | Phase 3 | 2 | Glaucoma, Rubeosis Iridis | AFLIBERCEPT, RANIBIZUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT00727038 | Lucentis for New Onset Neovascular Glaucoma | Phase 1/2 | 0 | Glaucoma, New Onset Glaucoma, Neovascular Glaucoma, New Onset Neovascular Glaucoma | RANIBIZUMAB | Its record names the disease | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0019783/trials